SCHEMBL20182222

SCHEMBL20182222

CCC(/C(=C/Nc1ccc(F)c(F)c1)N=N)n1cc(-c2cc(F)cnc2OC)c2c(N)ncnc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 4/20 0.34
EIF2AK3 Q9NZJ5 2/20 0.33
EGFR P00533 3/20 0.32
ABL1 P00519 2/20 0.32
ABL2 P42684 2/20 0.32
RET P07949 6/20 0.32
SRC P12931 2/20 0.31
KDR P35968 2/20 0.31
PIK3CA P42336 2/20 0.31
TEK Q02763 1/20 0.31
PIK3CD O00329 1/20 0.31
PIK3CB P42338 1/20 0.31
PIK3CG P48736 1/20 0.31
PRKDC P78527 1/20 0.31
RIPK2 O43353 1/20 0.30
PDGFRB P09619 1/20 0.30
KIT P10721 1/20 0.30
FLT3 P36888 1/20 0.30
SIK1 P57059 1/20 0.30
RIPK4 P57078 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20182271 0.91 CFTR (0.35) AXLEIF2AK3EGFRABL1ABL2
SCHEMBL20182275 0.91 EGFR (0.36) AXLEIF2AK3EGFRABL1ABL2
SCHEMBL20182235 0.91 EIF2AK3 (0.34) AXLEIF2AK3EGFRABL1ABL2
SCHEMBL20182194 0.90 EIF2AK3 (0.36) EIF2AK3EGFRABL1ABL2RET
SCHEMBL20182289 0.89 NTRK1 (0.36) AXLEIF2AK3EGFRABL1ABL2
SCHEMBL20182191 0.85 ALK (0.34) AXLEIF2AK3EGFRABL1ABL2
SCHEMBL20182225 0.83 CFTR (0.39) AXLEGFRABL1ABL2RET
SCHEMBL20182292 0.83 NEK7 (0.37) EIF2AK3EGFRABL1ABL2SRC
SCHEMBL20182265 0.81 NTRK1 (0.36) AXLEIF2AK3EGFRABL1ABL2
SCHEMBL20182224 0.81 EGFR (0.39) EGFRABL1ABL2RETSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018094137-A1 PYRROLOPYRIMIDINES AS CFTR POTENTIATORS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) 2018-05-24 WO disclosed